RAC1 and neoplasm: Activated RAC1 mutations accelerate tumour growth, induces epithelial–mesenchymal transition (EMT), increases angiogenesis, and influences tumour microenvironment-mediated immune escape driving tumour metastasis and causing treatment failures [66,86,98,105–108].